View All HCPCS Sections

• C9070

  Injection, tafasitamab-cxix, 2 mg

• C9071

  Injection, viltolarsen, 10 mg

• C9072

  Injection, immune globulin (asceniv), 500 mg

• C9073

  Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

• C9074

  Injection, lumasiran, 0.5 mg

• C9075

  Injection, casimersen, 10 mg

• C9076

  Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

• C9077

  Injection, cabotegravir and rilpivirine, 2mg/3mg

• C9078

  Injection, trilaciclib, 1 mg

• C9079

  Injection, evinacumab-dgnb, 5 mg

• C9080

  Injection, melphalan flufenamide hydrochloride, 1 mg

• C9081

  Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

• C9082

  Injection, dostarlimab-gxly, 100 mg

• C9083

  Injection, amivantamab-vmjw, 10 mg

• C9084

  Injection, loncastuximab tesirine-lpyl, 0.1 mg

• C9085

  Injection, avalglucosidase alfa-ngpt, 4 mg

• C9086

  Injection, anifrolumab-fnia, 1 mg

• C9087

  Injection, cyclophosphamide, (auromedics), 10 mg

• C9088

  Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg

• C9089

  Bupivacaine, collagen-matrix implant, 1 mg

• C9090

  Injection, plasminogen, human-tvmh, 1 mg

• C9091

  Injection, sirolimus protein-bound particles, 1 mg

• C9092

  Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg

• C9093

  Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg

• C9094

  Inj, sutimlimab-jome, 10 mg

• C9095

  Inj, tebentafusp-tebn, 1 mcg

• C9096

  Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram

• C9097

  Inj, faricimab-svoa, 0.1 mg

• C9098

  Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

• C9101

  Injection, oliceridine, 0.1 mg

• C9113

  Injection, pantoprazole sodium, per vial

• C9121

  Injection, argatroban, per 5 mg

• C9122

  Mometasone furoate sinus implant, 10 micrograms (sinuva)

• C9132

  Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity

• C9133

  Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.

• C9134

  Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.

• C9135

  Factor ix (antihemophilic factor, recombinant), alprolix, per i.u.

• C9136

  Injection, factor viii, fc fusion protein, (recombinant), per i.u.

• C9137

  Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u.

• C9138

  Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u.

• C9139

  Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u.

• C9140

  Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u.

• C9141

  Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u.

• C9142

  Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg

• C9143

  Cocaine hydrochloride nasal solution (numbrino), 1 mg

• C9144

  Injection, bupivacaine (posimir), 1 mg

• C9145

  Injection, aprepitant, (aponvie), 1 mg

• C9146

  Injection, mirvetuximab soravtansine-gynx, 1 mg

• C9147

  Injection, tremelimumab-actl, 1 mg

• C9148

  Injection, teclistamab-cqyv, 0.5 mg

---

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/3/2026

CPT^® is a registered trademark of the American Medical Association (AMA). All rights reserved.